These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12113695)

  • 1. [Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
    Bassand JP
    Rev Esp Cardiol; 2002 Jul; 55(7):697-702. PubMed ID: 12113695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 3. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ; Topol EJ
    Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
    Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.
    Kandzari DE; Califf RM
    Curr Opin Cardiol; 2002 Jul; 17(4):332-9. PubMed ID: 12151865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
    Araujo R; Agustí A
    Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
    [No Abstract]   [Full Text] [Related]  

  • 11. What have We learned from ESPRIT? What will we learn from TARGET?
    Ferguson JJ
    J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB; Newman AR; Raco DL
    Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
    Chew DP; Moliterno DJ
    Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing antiplatelet therapy in coronary interventions.
    King SB
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-8-13. PubMed ID: 11129685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.